Q3 EPS Estimate for Fennec Pharmaceuticals Lifted by Analyst

Fennec Pharmaceuticals Inc. (TSE:FRX) – Equities researchers at Wedbush raised their Q3 2025 earnings estimates for Fennec Pharmaceuticals in a research note issued on Sunday, December 22nd. Wedbush analyst D. Nierengarten now expects that the biopharmaceutical company will post earnings per share of $0.56 for the quarter, up from their prior forecast of $0.46. The consensus estimate for Fennec Pharmaceuticals’ current full-year earnings is $0.60 per share. Wedbush also issued estimates for Fennec Pharmaceuticals’ FY2026 earnings at $3.03 EPS and FY2027 earnings at $4.06 EPS.

Separately, Stephens upgraded Fennec Pharmaceuticals to a “strong-buy” rating in a report on Monday, November 18th.

Fennec Pharmaceuticals Price Performance

Shares of TSE FRX opened at C$8.93 on Tuesday. The company has a fifty day moving average price of C$7.19 and a 200 day moving average price of C$7.67. The firm has a market cap of C$244.32 million, a PE ratio of 89.30 and a beta of 0.25. The company has a current ratio of 8.02, a quick ratio of 10.17 and a debt-to-equity ratio of 1,040.68. Fennec Pharmaceuticals has a 1-year low of C$5.65 and a 1-year high of C$15.43.

Insiders Place Their Bets

In other Fennec Pharmaceuticals news, Director Rostislav Christov Raykov purchased 25,000 shares of the business’s stock in a transaction on Friday, December 20th. The shares were purchased at an average cost of C$3.87 per share, with a total value of C$96,840.00. Also, Senior Officer Robert Christopher Andrade acquired 15,816 shares of Fennec Pharmaceuticals stock in a transaction dated Monday, November 18th. The shares were acquired at an average price of C$3.43 per share, with a total value of C$54,248.88. Insiders bought a total of 41,612 shares of company stock valued at $157,868 in the last quarter. 16.20% of the stock is currently owned by insiders.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.